TheraBionic
Private Company
Funding information not available
Overview
TheraBionic is a private, commercial-stage oncology company focused on a novel, non-invasive treatment modality using tumor-specific radiofrequency electromagnetic fields. Its lead product, the TheraBionic P1, is indicated for patients with advanced hepatocellular carcinoma who have failed or are intolerant to first and second-line therapies, positioning it as a late-line treatment option. The technology, co-invented by founders Boris Pasche and Alexandre Barbault, aims to block tumor growth without significant side effects. The company appears to be in an early commercial or limited-access phase, with the device available by prescription.
Technology Platform
Proprietary technology using tumor-specific, amplitude-modulated radiofrequency electromagnetic fields (0.1 Hz to 150 kHz) to identify and therapeutically target cancer cells with selective growth inhibition and minimal side effects.
Opportunities
Risk Factors
Competitive Landscape
In advanced HCC, TheraBionic P1 competes with other late-line systemic therapies like regorafenib, cabozantinib, and ramucirumab, as well as emerging immuno-oncology combinations. Its primary differentiation is its non-pharmacological mechanism, favorable side-effect profile, and at-home administration. However, it faces the challenge of competing against established drug paradigms supported by larger clinical datasets.